NCT00861601View on ClinicalTrials.gov

Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Liver Diseases
Interventions
DRUG

eltrombopag 12.5 milligrams (mg) tablet

eltrombopag 12.5 mg tablet once a day

DRUG

eltrombopag 25 mg tablet

eltrombopag 25 mg tablet once a day

Trial Locations (10)

810-8563

GSK Investigational Site, Fukuoka

814-0180

GSK Investigational Site, Fukuoka

815-8555

GSK Investigational Site, Fukuoka

830-0011

GSK Investigational Site, Fukuoka

839-0863

GSK Investigational Site, Fukuoka

890-8520

GSK Investigational Site, Kagoshima

860-8556

GSK Investigational Site, Kumamoto

862-8655

GSK Investigational Site, Kumamoto

856-8562

GSK Investigational Site, Nagasaki

879-5593

GSK Investigational Site, Ōita

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY